News
Keytruda Approved as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
The approval was based on data from the phase 3 KEYNOTE-826 trial.
Your search for bevacizumab returned 75 results
ESMO 2021, News
Pembrolizumab Plus Chemo ± Bevacizumab Prolonged Survival in Cervical Cancer
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
ESMO 2021, News
Immunotherapy Significantly Improved Survival in Recurrent/Metastatic Cervical Cancer
The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.
ESMO 2021, News
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
News
Some Cancer Drugs Without Proven Benefit Still Recommended
Six of 18 indications remain on label for cancer drugs that failed to improve primary end point in trials after receiving accelerated approval
Drugs in the Pipeline
Tisotumab Vedotin Under Review for Recurrent or Metastatic Cervical Cancer
Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.
News
Anti-VEGF Injections May Reduce Glaucoma Burden for Some
Study shows reductions in intraocular pressures and antiglaucoma medication use.
News
Low Doses of Bevacizumab Tested for Retinopathy of Prematurity
Phase 1 study suggests that intravitreous injection of 0.004mg may be lowest effective dose.
News, Oncology
QoL Extended With Atezolizumab + Bevacizumab in Liver Cancer
And, triplet and doublet drug regimens delay decline in quality of life in BRAF V600E metastatic CRC.
News
Adding Bevacizumab May Improve Overall Survival in NSCLC
Addition of bevacizumab to carboplatin/pemetrexed beneficial in advanced non-small cell lung cancer
